The nonclassical major histocompatibility complex class II molecule HLA-DM (DM) has recently been shown to play a central role in the class 11-associated antigen presentation pathway: DM releases invariant chain-derived CLIP peptides (class II-associated invariant chain protein peptide) from HLA-DR (DR) molecules and thereby facilitates loading with antigenic peptides. Some observations have led to the suggestion that DM acts in a catalytic manner, but so far direct proof is missing. Here, we investigated in vitro the kinetics of exchange of endogenously bound CLIP for various peptides on DR1 and DR2a molecules: we found that in the presence ofDM the peptide loading process follows MichaelisMenten kinetics with turnover numbers of 3-12 DR molecules per minute per DM molecule, and with KM values of 500-1000 nM. In addition, surface plasmon resonance measurements showed that DM interacts efficiently with DR-CLIP complexes but only weakly with DR-peptide complexes isolated from DM-positive cells. Taken together, our data provide evidence that DM functions as an enzyme-like catalyst of peptide exchange and favors the generation of long-lived DR-peptide complexes that are no longer substrates for DM.
Immediately after biosynthesis in the endoplasmic reticulum, major histocompatibility complex (MHC) class II molecules associate with the invariant chain (Ii) (1) , which prevents the MHC class II peptide binding groove from association with peptides (2) or polypeptides (3) . A sorting signal in the cytoplasmic tail of Ii targets MHC class II molecules to endosomal compartments (4) , where stepwise proteolytical degradation of Ii takes place (5) . The final fragment of Ii that stays associated with class II molecules is designated CLIP (class II-associated invariant chain peptide) and encompasses residues 81-105 of the p33 form of human Ii (6) . Since CLIP occupies the peptide binding groove (7, 8) , its removal is a prerequisite for loading of MHC class II molecules.
From some class II alleles, CLIP can rapidly dissociate by itself at endosomal pH (7, 9, 10) . However, analysis of mutant antigen presenting cell lines that mainly displayed HLA-DR (DR)-CLIP complexes instead of DR-self-peptide complexes (6, 11) led to the identification of the nonclassical MHC class II molecule HLA-DM (DM) (12) as a key player involved in the peptide loading process (13, 14) . Subcellular fractionation and immunoprecipitation studies have revealed that DM can physically associate with DR molecules (15) , and in vitro experiments have shown that DM enhances CLIP release from DR (16, 17) , but the mechanism is still unknown. It has been speculated that DM may act as a CLIP acceptor or a peptide shuttle, but recent studies have suggested that DM functions substoichiometrically and, therefore, may act as a catalyst (18, 19) . However, so far there is no formal evidence for the catalytic nature of DM.
In the present study we demonstrate that DM catalyzes the peptide exchange processes in an enzyme-like fashion following Michaelis-Menten kinetics. The peptide exchange is terminated once a kinetically stable peptide has been loaded onto the class II molecule, indicating that the catalytic action of DM favors the generation of long-lived class II-peptide complexes that will then accumulate at the cell surface.
MATERIALS AND METHODS Cells. The Epstein-Barr virus-transformed homozygous B cell lines WT-100 (DRlDwl), LD2B (DR15Dw2), and COX (DR17Dw3) as well as the T x B hybrid cell line T2 transfected with the cDNA for DR1 (DRA*0101/ DRB1*0101), DR2a (DRA*01O1/DRB5*0101), or DR3 (DRA*0101/DRB1*0301) were used for the isolation of the respective DR molecules. Cell lines were maintained in roller bottles at 37°C and cultured in RPMI 1640 medium with 20 mM Hepes (GIBCO) containing 10% heat-inactivated fetal calf serum (Konco Laboratories, Wiesbaden, Germany).
Peptides. The following peptides were synthesized and labeled with the fluorophor 7-amino-4-methylcoumarin-3-acetic acid (AMCA; Lambda Fluorescence Technology, Graz, Germany) as described (20) : CLIP(81-105), LPKPPKPVSK-MRMATPLLMQALPMG [a synthetic peptide containing residues 81-105 of human Ii (p33 form)]; DQw6(43-58), DVGVYRAVTPQGRPDA (a synthetic peptide containing residues 43-58 of HLA-DQw6); HA(307-319), PKYVKQNTLKLAT (synthetic peptide containing residues 307-319 of influenza virus hemagglutinin); and MBP(87-99), VHFFKNIVTPRTP (synthetic peptide containing residues 87-99 of human myelin basic protein).
Purification of DR Molecules. HLA-DR molecules were isolated from B-cell lines or T2 transfectants by affinitychromatography using anti-DR mAb L243, as described (7) .
Purification of HLA-DM. HLA-DM was affinity-purified using the protocol described, for DR molecules, with the following modifications: 200 g of human spleen (containing -1011 cells) from a patient with B-chronic lymphocytic leukemia were homogenized and extracted for 2 h on ice in 1.0% Nonidet P-40. The lysate was applied to a Sepharose CL-4B column to which the monoclonal anti-DM antibody DM.K8 (directed against the cytoplasmic tail of the HLA-DM,B chain) Abbreviations: AMCA, 7-amino-4-methyl-coumarin-3-acetic acid; CLIP, class II associated invariant chain peptides; CLIP(81-105), synthetic peptide containing residues 81-105 of human Ii (p33 form); DM, HLA-DM; DR, HLA-DR; DQw6(43-58), synthetic peptide containing residues 43-58 of HLA-DQw6; HA(307-319), synthetic peptide containing residues 307-319 of influenza virus hemagglutinin; HLA, human leucocyte antigen; HIPSEC, high-performance size exclusion chromatography; Ii, invariant chain; MALDI-MS, matrix-assisted laser desorption ionization-mass spectrometry; MBP (87-99), synthetic peptide containing residues 87-99 of human myelin basic protein; MHC, major histocompatibility complex. tA.B.V. and H.K. contributed equally to this work. *To whom reprint requests should be addressed.
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was coupled. HLA-DM was eluted in 0.1% Zwittergent-12 (Calbiochem), 100 mM sodium phosphate, 50 mM sodium acetate (pH 5.0), yielding -250 ,ug HLA-DM. Purity of the isolated material was higher than 90%, as assessed by SDS/ PAGE.
Mass Spectrometry. Self-peptides bound to purified DR molecules were analyzed by matrix-assisted laser desorption ionization-mass spectrometry (MALDI-MS) as described (10) .
Peptide Binding Assay. Purified DR molecules and the respective AMCA-labeled peptide were coincubated in the absence or presence of purified DM for the indicated times at 37°C in 50 mM sodium phosphate, 50 mM sodium citrate, 0.1% Zwittergent-12 (pH 5.0). Binding was quantitated by high performance size-exclusion chromatography (HPSEC) as described (7).
Soluble DM. HLA-DM molecules lacking the transmembrane and the cytoplasmic region were produced in Spodoptera frugiperda (Sf9) cells and isolated as decribed (16) .
BlAcore Analysis. Real time analysis of DM-DR interaction was performed in a BIAcore2000 biosensor (Pharmacia Biosensor, Upsala). Soluble DM molecules were immobilized in a BIAcore2000 flow cell by standard amine-targeted chemistry by activating the carboxy-detran layer as described (21) . DM was coupled via the active esters by injection into the flow cell in 10 mM acetate (pH 4.5) until 4000-5000 resonance units were bound. The surface was inactivated with ethanolamine. Measurements were performed by injection of different amounts of DR molecules in 50 mM sodium phosphate, 50 mM citrate, 1% octyl glucoside (pH 5.1) at a flow rate of 5 gl/min over the DM surface and simultaneously over a control surface. Background binding was subtracted from the data presented in Fig. 4 . The DM surface was regenerated by injecting binding buffer (pH 7.4).
RESULTS AND DISCUSSION
DR-CLIP Complexes Are Substrates for DM. The removal of CLIP from HLA-DR molecules seems to be a pivotal step in the peptide loading process which involves the action of DM. Therefore, for the in vitro investigation of the kinetics of DM-mediated peptide exchange purified DR-CLIP complexes were employed. DR2a molecules isolated from DM-negative T2 cells transfected with DR2a (DRA*0101/DRB5*0101) are exclusively occupied by CLIP variants (Fig. 1 Upper): analysis of the self-peptide fraction by MALDI-MS revealed that all six mass species correspond to CLIP truncation variants. Very similar CLIP variants have been described for DR3 molecules from T2 transfectants (6, 11) . For comparison, the mass profile of DR2-associated self-peptides isolated from the DM-positive Epstein-Barr virus-transformed B-cell line LD2B is given in Fig. 1 Lower: a typical distribution of peptides with mass-tocharge ratios of m/z = 1400 to 2800, corresponding to 12-mers to 25-mers, is found, with a broad maximum around m/z = 1800, consistent with other reports (22) .
DR2a-DQw6(43-58) Complexes Are Stable in the Presence of DM. Using an in vitro peptide binding assay based on HPSEC, we analyzed the time of half-maximal dissociation tl/2,off of different peptides bound to DR2a at endosomal pH 5.0 in the absence and presence of DM. Dissociation of CLIP(81-105) from DR2a was found to be very fast (til/2,off 10 min), but even faster in the presence of DM (ti/2,off 3 min) (Fig. 2) .
The experiment was performed in the presence of the detergent Zwittergent, which has been described to increase the off-rate of CLIP (10) . Nevertheless, also under these conditions, the dissociation of CLIP is enhanced by DM, but not the dissociation of the DQw6(43-58) peptide. The DM-sensitivity of the DR2a-CLIP complex is consistent with the findings described for other DR-CLIP complexes (16, 17, 19) , although the CLIP dissocation rates may vary depending on the detergent used (10, 23) . In contrast, DM did not affect the disso- ciation rate of DQw6(43-58), abbreviated as DQw6 peptide, a DR2-associated self-peptide (22, 24) , which bound to DR2a with a slow off-rate (tl/2,off 2400 min; Fig. 2 ). Thus, the intrinsically stable DR2a-DQw6 peptide complex is DMinsensitive, which is reminiscent of the previously described DR1-HA(307-319) complex (16) . The finding that the kinetically stable DQw6 self-peptide DQw6(43-58) was resistant to DM-mediated removal, whereas the low-stability CLIP peptide was not is consistent with the hypothesis that DM may function as a peptide editor in the class II loading compartment by skewing the self-peptide repertoire toward stably binding peptides.
The Michaelis-Menten Model. Recent data suggested that substoichiometric amounts of natural DM were sufficient to enhance formation of SDS-stable MHC class II a13-peptide complexes in vitro (19) , but in another study an excess of recombinant DM was necessary to demonstrate enhanced loading (16) . To address the question of whether DM acts as a catalyst, we tested, by using HPSEC, whether DM-mediated peptide loading of DR molecules would follow classical Michaelis-Menten kinetics. According to the kinetic model of , the DM-mediated peptide exchange should obey the equation given in Fig. 3A , which can be described as follows: DR-CLIP complexes serve as the substrate for DM, thereby forming an intermediary DM-DR-CLIP complex (step I). The association of DM leads to release of CLIP while DM stays bound to DR (step II). The DM-DR complex is formally equivalent to an enzyme-substrate complex. At this stage, rebinding of CLIP is still possible, accounting for the observation that also the binding of CLIP is accelerated by DM (16) . However, in the presence of sufficient amounts of other peptides, loading of the latter will be catalyzed (step III). To fulfill the Michaelis-Menten model (25) , the formation of the DR-peptide complex has to proceed unidirectionally, meaning that the final DR-peptide complex should not serve as a substrate for DM-facilitated dissociation. Since the DQw6 peptide loaded onto DR2a revealed to be DM-insensitive (Fig. 2) Vma. was unaffected (Fig. 3C and Table 1 ). This is indicative of competitive inhibition.
In contrast, DR3-peptide complexes isolated from a DMpositive B-cell line were found to be only weak competitive inhibitors ( Fig. 3C (Fig. 3D) . Like DR2a from T2 cells (see Fig. 1 1 DR2a (jIM) 10 12 FIG. 3. Michaelis-Menten kinetics of DM-mediated peptide exchange. (A) Equation for the DM-mediated peptide exchange. According to the Michaelis-Menten model, DR-CLIP is the substrate that forms a complex with DM (step I). This step of the reaction achieves equilibrium with the educts and with the DM-DR complex that is formed upon dissociation of CLIP (step II).
Step III, where peptide binding is accompanied by release of DM, has to proceed unidirectionally, per definition. (B) Effect of DM on the velocity of DQw6(43-58) peptide loading onto DR2a.
Binding of the self-peptide DQw6(43-58) (-, *, and A, 2 jiM; or O, 20 jiM) to DR2a (60-600 nM) from T2 cells in the presence of HLA-DM (-and C, 8 nM; *, 20 nM; *, 60 nM) was measured after 3 min of incubation at pH 5.0 and 37°C by HPSEC. Binding in the absence of DM does not exceed background levels with 2,iM peptide; in the case of the 20 jiM peptide, the uncatalyzed binding (attaining up to 25% of catalyzed binding) was subtracted. Initial rates of loading were plotted versus the amount of DR2a in a double reciprocal diagram according to . Catalytic parameters as the Michaelis constant, KM, and the maximal velocity of loading, Vmax, were calculated from the intercept of the linear regression curve y = a + bx with the x axis (= -1/KM) and the x axis (= 1 /Vmax), respectively. Values calculated for KM and Vm are given in Table 1 Real-Time Analysis of the DM-DR Interaction. Surface plasmon resonance is a spectroscopic technique which allows the investigation of protein-protein interactions in real time (29) . In particular, this technique is suitable for the kinetic analysis of short-lived or low-affinity complexes. To visualize putative DM-DR complexes, recombinant DM molecules were generated in a baculovirus expression system (16) , purified, and covalently immobilized on the chip surface of the biosensor. DR-CLIP complexes were then passed over the immobilized DM molecules at pH 5.1, 25°C. As shown in Fig.  4A and B, DR1-CLIP as well as DR2a-CLIP complexes from T2 cells interacted with DM in a dose-dependent manner.
Since the dissociation of the bound DR molecules was quite slow (tl/2,off 25 min), a calculation of the kinetic parameters for the DM-DR interaction was not possible. Obviously, dissociation of DR molecules from DM is not favored at 25°C and pH 5 in the absence of exogenous peptides.
Importantly, DR-peptide complexes isolated from DMpositive B-cell lines WT-100 and LD2B revealed to interact less well with DM compared with DR-CLIP complexes (Fig.  4 C and D) . These data reinforce the conclusions drawn from the failure of kinetically stable DR-peptide complexes to act as competitive inhibitors of the Michaelis-Menten kinetics (cf. Fig. 3C ) and strongly suggest that DM cannot efficiently The data presented here support the idea that DM prolongs the half-life of an otherwise short-lived conformer of the class II af3 dimer that is favorable for unloading as well as for loading. Most likely this conformer displays a more "open" state of the peptide binding groove. Consequently, all potentially binding peptides are expected to associate with increased efficiency in the presence of DM. This was indeed found in the present study (cf. Fig. 3 ) and in previous studies (16, 17 (Figs. 2  and 3C ). In the plasmon resonance experiments shown in Fig.  4 , preferentially low-stability DR-CLIP complexes were able to associate with immobilized DM and to act as a competitor in the Michaelis-Menten studies. However, far fewer DRpeptide complexes isolated from DM-positive cells, which can be assumed to contain a sizable fraction of high-stability complexes, were able to bind to DM and function as competitors. Thus, in acidic endosomal/lysosomal compartments DM favors the generation of long-lived class II-peptide complexes for efficient presentation to T cells at the cell surface.
